SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-062782
Filing Date
2023-08-03
Accepted
2023-08-03 08:20:28
Documents
62
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0623_protaratherap.htm   iXBRL 10-Q 837136
2 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT, ENTERED INTO AS OF JUNE 1, f10q0623ex10-1_protaratherap.htm EX-10.1 63343
3 CERTIFICATION f10q0623ex31-1_protaratherap.htm EX-31.1 12923
4 CERTIFICATION f10q0623ex31-2_protaratherap.htm EX-31.2 12955
5 CERTIFICATION f10q0623ex32-1_protaratherap.htm EX-32.1 7053
  Complete submission text file 0001213900-23-062782.txt   4208022

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE tara-20230630.xsd EX-101.SCH 45828
7 XBRL CALCULATION FILE tara-20230630_cal.xml EX-101.CAL 36746
8 XBRL DEFINITION FILE tara-20230630_def.xml EX-101.DEF 191173
9 XBRL LABEL FILE tara-20230630_lab.xml EX-101.LAB 387539
10 XBRL PRESENTATION FILE tara-20230630_pre.xml EX-101.PRE 204195
56 EXTRACTED XBRL INSTANCE DOCUMENT f10q0623_protaratherap_htm.xml XML 421711
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36694 | Film No.: 231138218
SIC: 2836 Biological Products, (No Diagnostic Substances)